If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen ...

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo ...

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

A new weight-loss jab will be rolled out on the NHS in England - but it could take 12 years for everyone to receive it, the NHS drugs advisory body says. The National Institute for Health and Care ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical trial, Lilly said in a release Wednesday.

Social media platforms have become a marketplace for individuals selling leftover or second-hand supplies of these drugs.

Last year’s study in the journal Obesity had revealed that of people prescribed weight-loss drugs, just 44 per cent were ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

MariTide was administered monthly or less frequently, which could provide an edge over the popular weekly injections ...